Foghorn Therapeutics Inc. (FHTX) — Financial statements
Income statement, balance sheet, and cash flow for Foghorn Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 31↑36.8% | 23↓33.8% | 34↑77.6% | 19↑1357.8% | 1 | |
| Cost of Revenue | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 28↑22.0% | 23↓33.8% | 34↑77.6% | 19↑1357.8% | 1 | |
| Operating Expenses | ||||||
| R&D Expenses | 85↓9.6% | 95↓13.8% | 110↑3.9% | 106↑31.5% | 80 | |
| General & Administrative Expenses | 28↓2.9% | 28↓12.4% | 32↑5.3% | 31↑41.5% | 22 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 28↓2.9% | 28↓12.4% | 32↑5.3% | 31↑41.5% | 22 | |
| Other Expenses | -3↓238.9% | 2 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 110↓12.5% | 125↓11.8% | 142↑4.2% | 136↑33.6% | 102 | |
| Total Costs & Expenses | 113↓9.8% | 125↓11.8% | 142↑4.2% | 136↑33.6% | 102 | |
| Operating Results | ||||||
| Operating Income | -82↑20.0% | -103↑4.8% | -108↑7.9% | -117↓16.3% | -101 | |
| Depreciation & Amortization | 3↑6.8% | 3↓9.6% | 3↑3.9% | 3↑2.9% | 3 | |
| EBITDA | -79↑18.9% | -97↑7.0% | -104↑8.2% | -114↓18.3% | -96 | |
| EBIT | -82↑18.1% | -100↑7.1% | -108↑7.9% | -117↓17.8% | -99 | |
| Interest & Other Income | ||||||
| Net Interest Income | 9↓26.5% | 12↑9.4% | 11↑91.6% | 6↑407.3% | -2 | |
| Interest Income | 9↓26.5% | 12↑9.4% | 11↑91.6% | 6↑9518.6% | 0.06 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 2 | |
| Non-Operating Income | 0.00↑100.0% | -2 | 0.00 | 0.00↑100.0% | -1 | |
| Other Income / Expenses | 8↓51.3% | 16↑17.2% | 14↑66.0% | 8↑1508.7% | -0.59 | |
| Income Before Tax | -74↑14.2% | -87↑8.0% | -94↑13.5% | -109↓7.5% | -101 | |
| Income Tax Expense | 0.00 | 0.00↓100.0% | 4 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -74↑14.2% | -87↑12.0% | -98↑9.6% | -109↓7.5% | -101 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -74↑14.2% | -87↑12.0% | -98↑9.6% | -109↓7.5% | -101 | |
| Bottom-Line Net Income | -74↑14.2% | -87↑12.0% | -98↑9.6% | -109↓7.5% | -101 | |
| EPS (Basic) | -1.18↑25.3% | -1.58↑32.5% | -2.34↑10.7% | -2.62↑5.8% | -2.78 | |
| EPS (Diluted) | -1.18↑25.3% | -1.58↑32.5% | -2.34↑10.7% | -2.62↑5.8% | -2.78 | |
| Weighted Average Shares | 63↑14.7% | 55↑30.8% | 42↑0.9% | 42↑11.9% | 37 | |
| Weighted Average Diluted Shares | 63↑14.7% | 55↑30.8% | 42↑0.9% | 42↑11.9% | 37 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.